IRIX Stock Overview
An ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
IRIDEX Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$3.65 |
| 52 Week Low | US$1.27 |
| Beta | 0.84 |
| 1 Month Change | -6.63% |
| 3 Month Change | -11.93% |
| 1 Year Change | -41.06% |
| 3 Year Change | -66.59% |
| 5 Year Change | -52.45% |
| Change since IPO | -84.88% |
Recent News & Updates
Recent updates
Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive
Jun 11
Is IRIDEX (NASDAQ:IRIX) In A Good Position To Invest In Growth?
May 14Iridex's Strategic Review Process Should Bear Fruit 'Soon'
Mar 28Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues
Feb 14Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
Oct 04Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop
Aug 12Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
Apr 14We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely
Oct 12Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?
Feb 25Iridex To Benefit From New Revolutionary Glaucoma Treatment
Jan 11Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long
Jan 03IRIDEX says laser therapy now accepted in the European Glaucoma Society guidelines
Dec 23Shareholder Returns
| IRIX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.7% | 0.7% | 1.5% |
| 1Y | -41.1% | 13.0% | 22.4% |
Return vs Industry: IRIX underperformed the US Medical Equipment industry which returned 12.9% over the past year.
Return vs Market: IRIX underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| IRIX volatility | |
|---|---|
| IRIX Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IRIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IRIX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 111 | Patrick Mercer | www.iridex.com |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.
IRIDEX Corporation Fundamentals Summary
| IRIX fundamental statistics | |
|---|---|
| Market cap | US$25.79m |
| Earnings (TTM) | -US$11.04m |
| Revenue (TTM) | US$48.43m |
0.5x
P/S Ratio-2.3x
P/E RatioIs IRIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRIX income statement (TTM) | |
|---|---|
| Revenue | US$48.43m |
| Cost of Revenue | US$29.63m |
| Gross Profit | US$18.80m |
| Other Expenses | US$29.84m |
| Earnings | -US$11.04m |
Last Reported Earnings
Sep 28, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 38.82% |
| Net Profit Margin | -22.79% |
| Debt/Equity Ratio | 105.1% |
How did IRIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 02:32 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/28 |
| Annual Earnings | 2023/12/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IRIDEX Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Roth Capital Partners |
| Joseph Munda | Sidoti & Company, LLC |
| Lisa Springer | Singular Research |